Urotensin II evokes potent vasoconstriction in humans in vivo

Br J Pharmacol. 2002 Jan;135(1):25-7. doi: 10.1038/sj.bjp.0704448.


The peptide urotensin II (U II) evokes potent vasoconstriction in non-human primates. In human blood vessels studied in vitro variable effects of U II are reported; vasoconstriction, vasodilatation or no response. It is therefore of importance to determine the vascular effect of U II in humans in vivo. U II (0.1 - 300 pmol min(-1)) was infused into the brachial artery of nine healthy volunteers. Changes in forearm blood flow (FBF) were determined by venous occlusion plethysmography. U II induced dose-dependent reduction in FBF. A threshold response was obtained by 1 pmol min(-1), and the highest dose of U II (300 pmol min(-1)) reduced FBF by 31+/-4% (P<0.01). FBF returned to baseline values within 30 min. This study demonstrates that U II produces potent vasoconstriction in humans in vivo.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Flow Velocity / drug effects
  • Brachial Artery / physiology
  • Dose-Response Relationship, Drug
  • Forearm / blood supply*
  • Heart Rate / drug effects
  • Humans
  • Infusions, Intra-Arterial
  • Male
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology
  • Plethysmography
  • Regional Blood Flow
  • Urotensins / administration & dosage
  • Urotensins / blood
  • Urotensins / pharmacology*
  • Vasoconstriction / drug effects*
  • Vasoconstrictor Agents / administration & dosage
  • Vasoconstrictor Agents / blood
  • Vasoconstrictor Agents / pharmacology*


  • Urotensins
  • Vasoconstrictor Agents
  • urotensin II